← Leaderboards
Matthew Scott Painschab
Univ Of North Carolina Chapel Hill
$1,808,165
Attributed
$1,808,165
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $544.3K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,808,165 · 2
By mechanism
DP1$1,088,500 · 1
K01$719,665 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Nora Rosenberg$4,362,163
- Lisa C. Lindley$3,544,142
- Katherine Douglas Westmoreland$768,155
- Stephanie Brooke Wheeler$7,793,710
- Joseph David Tucker$13,115,535
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsComorbidityMalawiNewly DiagnosedHuman Herpesvirus 8Africa South Of The SaharaEnrollmentLymphoproliferative DisordersMulticentric Angiofollicular Lymphoid HyperplasiaPrevalenceAntiretroviral TherapyCessation Of LifeCapitalCancer CareAids Related CancerAwardBurden Of IllnessAdverse EventCommon Terminology Criteria For Adverse EventsB-LymphocytesCitiesClinical ResearchClinical Practice GuidelineChemotherapy
Grant awards (7)
Innovations in diagnosis for lymphadenopathy across HIV Centers of Excellence in Malawi$544,250
DP1 · FY2025 · CA · contact PI
Innovations in diagnosis for lymphadenopathy across HIV Centers of Excellence in Malawi$544,250
DP1 · FY2024 · CA · contact PI
Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in Malawi$143,933
K01 · FY2023 · TW · contact PI
Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in Malawi$143,933
K01 · FY2022 · TW · contact PI
Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in Malawi$143,933
K01 · FY2021 · TW · contact PI
Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in Malawi$143,933
K01 · FY2020 · TW · contact PI
Safety, efficacy, and cost-effectiveness of rituximab for multicentric Castleman disease in Malawi$143,933
K01 · FY2019 · TW · contact PI